|
|
|||||||||
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail. Notice to Readers Establishment of VARIVAX{Registered} Pregnancy RegistryVARIVAX{Registered} * (Merck & Co., Inc. {West Point, Pennsylvania}), a live attenuated virus vaccine for preventing chickenpox, recently has been licensed for children aged greater than or equal to 12 months. Adults without a reliable history of chickenpox also can receive the vaccine. However, because no data exist about the effects of VARIVAX{Registered} on fetal development and because natural varicella infection can cause a complex of congenital anomalies (i.e., congenital varicella syndrome), the package circular states that VARIVAX{Registered} should not be administered during pregnancy and that pregnancy should be avoided for at least 3 months after vaccination. Merck & Co., Inc., in collaboration with CDC, has established a registry to follow the outcomes of pregnancy when women are vaccinated within 3 months before pregnancy or at any time during pregnancy. Patients and health-care providers should report any vaccinations with VARIVAX{Registered} during this period to the registry, telephone (800) 986-8999; mailing address, Merck Research Labs, Worldwide Product Safety & Epidemiology, BLA-31, West Point, PA 19486. Questions regarding the registry should be directed to Dr. Jeanne Manson at this address; telephone (610) 397-7290 (collect); or fax (610) 397-2328. An annual report will be sent to health-care providers participating in the registry.
Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.Page converted: 09/19/98 |
|||||||||
This page last reviewed 5/2/01
|